Moderna said Thursday that its potential coronavirus vaccine is showing good signs of producing antibodies in elderly patients, CNBC reports

What’s going on?

  • Moderna said it tested the vaccine on 10 adults who were between 56 and 70 years old, as well as 10 elderly adults who were 71 and older, according to CNBC.
  • These participants received two 100 microgram doses of the vaccine within a 28-day span.
  • The vaccine reportedly added antibodies into the patients’ symptoms, which could be necessary to stop the novel coronavirus, according to CNBC.
Related
Who gets a vaccine?
If the COVID-19 vaccine is this successful, then we can return to normal, study says
  • Patients reportedly felt fatigue, chills, headaches and pain where they were injected. The symptoms resolved in two days.
  • Unsurprisingly, Modern shares jumped 6% in trading on Wednesday.

Bigger picture:

The new results come as Moderna has begun testing the coronavirus vaccine on at least 30,000 volunteers, according to Deseret.com.

Related
How many Americans say they’ll get the coronavirus vaccine?

Moderna chief executive officer Stephane Bancel told Bloomberg that Moderna it is “totally on track” for getting all 30,000 patients into the trial by the end of September.

  • “Now we are really going at full speed.”

Health officials hope there will be a COVID-19 vaccine by the end of the year, according to WBUR. There have been no guarantees from scientists.